Biopharma AI
By
Is Novartis Deepening Its Bet on AI-Enabled Molecular Glue Degraders Through an Expanded Collaboration With Monte Rosa?
Novartis AG (SIX: NOVN; NYSE: NVS), a global leader in immunology and targeted therapies, has broadened its partnership…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma – The Dawn of Robotics-Driven R&D at Scale?
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Could Chai’s $70 Million OpenAI-Backed Funding Propel the Next Leap in AI-Engineered Drug Discovery Success?
Key Highlights Breakthrough Funding and Industry BackingThe Series A round brings Chai Discovery’s total capital to $100 million,…
Can GHX’s AI-Driven Supply Chain Solutions Transform How Hospitals Tackle Disruptions?
Key Highlights AI reshaping healthcare supply chains: Unlike retail or tech, healthcare requires flawless delivery—any delay can directly…
Is Stanford’s MedAgentBench Setting the New Gold Standard for AI in Clinical Care?
Key Highlights AI benchmarking moves beyond knowledge tests: Unlike earlier evaluations that focused on exams like the USMLE,…
